Psoriasis is a progressive chronic autoimmune disease, predominantly affecting the skin. Changes in the skin which lead to psoriasis begin in the immune system when T cells are triggered and become overactive. These T cells act as if fighting an infection and in doing so produce inflammatory chemicals which trigger rapid proliferation of skin cells, causing psoriatic plaques to form.
There are five different types of psoriasis, plaque psoriasis which is the most common, guttate, inverse, pustular and erythrodermic. Erythrodermic psoriasis is the rarest form, occurring in only 3% of people who have psoriasis and can be life-threatening; therefore, awareness of the type of psoriasis allows the most appropriate form of treatment to be chosen for the patient. Severity of psoriasis is determined by the surface area of the skin affected. Treatment of moderate to severe psoriasis usually involves a combination of treatment strategies. Both early- and late-onset psoriasis patients can have mild, moderate or severe symptoms. The type and severity of psoriasis are vital in formulating an effective treatment plan and the Epiomic database sub-divides the patient population not only by the type and surface area affected, but also the age at onset to give this deep insight into the illness.
Psoriasis often coexists with other conditions such as obesity, type 2 diabetes and cardiovascular diseases. People with psoriasis are twice as likely to suffer from depression, most likely as a result of the psychological effects of the disease. Additionally, approximately 30 percent of people with psoriasis will eventually develop psoriatic arthritis. The Epiomic database can provide you with precise information about the presence of these co-morbidities and family history of psoriasis within the patient population along with arthritic involvement and common risk factors such as smoking to create a better understanding of the market landscape.